CDMO Pharmaterials has announced that it will quadruple its GMP manufacturing capacity and add a dedicated inhalation development laboratory as part of an expansion of its Reading, UK site. The expansion plans also include additions to existing analytical and stability facilities to support increased manufacturing, both for clinical trial and commercial activities.
According to the company, the first phase of the project, which includes 4 walk-in stability chambers, has already been completed and is in operation. The remainder of the project is expected to be complete by the end of 2014.
Pharmaterials Chief Operating Officer Shahid Raza said, “2014 will see a step change in the capacity of Pharmaterials. The established business and customer base gives us the confidence to invest and grow the UK business. As well as the expanding facilities and laboratories, we are also looking forward to creating many new high value jobs and look forward to welcoming new people to join the talented Pharmaterials team in the coming years.”
The company is looking to hire at least one new inhalation scientist.
Read the Pharmaterials announcement.
